Skip to main navigation Skip to search Skip to main content

Oral Administration of OKT3 MAb to Patients with NASH, Promotes Regulatory T-cell Induction, and Alleviates Insulin Resistance: Results of a Phase IIa Blinded Placebo-Controlled Trial

  • Gadi Lalazar
  • , Meir Mizrahi
  • , Ilit Turgeman
  • , Tomer Adar
  • , Ami Ben Ya’acov
  • , Yehudit Shabat
  • , Assy Nimer
  • , Nila Hemed
  • , Lidya Zolotarovya
  • , Yoav Lichtenstein
  • , Nadya Lisovoder
  • , Sarit Samira
  • , Itamar Shalit
  • , Ronald Ellis
  • , Yaron Ilan
  • Hadassah University Medical Centre
  • Albert Einstein College of Medicine
  • Shaare Zedek Medical Center
  • Rebecca Sieff Government Hospital
  • Therapix Biosciences

Research output: Contribution to journal › Article › peer-review

73 Scopus citations

Fingerprint

Dive into the research topics of 'Oral Administration of OKT3 MAb to Patients with NASH, Promotes Regulatory T-cell Induction, and Alleviates Insulin Resistance: Results of a Phase IIa Blinded Placebo-Controlled Trial'. Together they form a unique fingerprint.
Sort by

Keyphrases

Immunology and Microbiology